HD-OPM Archive
Topics › Weight, visceral & liver fat

GLP-1 drugs barely bend the obesity curve, Fontana argues, because culture drives obesity

Louis Nervegna · Dec 31, 2025 · ♥ 6 reactions · 2 comments · original Facebook post
Weight, visceral & liver fatGLP-1 drugs (semaglutide, tirzepatide)
AI summary & key facts

Luigi Fontana argues that even powerful GLP-1 drugs cannot offset a food environment of ultra-processed food, alcohol, snacking, big portions and low movement.

#obesitycrisisHD #glp1HD #obesityHD

This chart isn’t a drug story. It’s a culture story.

Even with powerful GLP-1s, the obesity curve barely flinches—because you can’t medicate your way out of a society that normalizes ultra-processed food, alchol, constant snacking, huge portions, screens over movement, and kids growing up with playstations and without food literacy.

Drugs can help some individuals to drop a few kg for sometime.
But culture sets the baseline.

Real, lasting change means changing norms: cooking again, eating real food, moving daily, and teaching kids what food and exercise is—and what it does.

No photo description available.
← newer: Laron syndrome, with lifelong low IGF-1 and mTOR, shows low older: New obesity definition classifies 75.2% of US adults as havi →